glycyl-arginyl-glycyl-aspartyl-serine has been researched along with Disease Models, Animal in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gong, F; Huang, M; Ji, S; Li, S; Tan, Y; Wan, L; Wan, Y; Wang, L; Yun, Z; Zhang, P; Zhang, S; Zhang, X; Zhu, X | 1 |
| He, Y; Li, H; Maharjan, A; Ren, X; Su, Y; Sun, X; Xu, J; York, P; Zhang, J | 1 |
2 other study(ies) available for glycyl-arginyl-glycyl-aspartyl-serine and Disease Models, Animal
| Article | Year |
|---|---|
GRGDS-functionalized chitosan nanoparticles as a potential intravenous hemostat for traumatic hemorrhage control in an animal model.
Topics: Animals; Chitosan; Disease Models, Animal; Female; Hemorrhage; Hemostatics; Liver; Male; Mice, Inbred BALB C; Nanoparticles; Oligopeptides; Polyethylene Glycols; Rats; Rats, Sprague-Dawley | 2018 |
Cuboidal tethered cyclodextrin frameworks tailored for hemostasis and injured vessel targeting.
Topics: Animals; Blood Platelets; Cell Adhesion; Cyclodextrins; Disease Models, Animal; Drug Delivery Systems; Hemorrhage; Hemostasis; Mice; Oligopeptides; Organometallic Compounds; Platelet Aggregation; Rats, Sprague-Dawley; Theranostic Nanomedicine; Treatment Outcome; Vascular Diseases | 2019 |